A prospective single centre, open label, pilot study to evaluate the safety of ICXP007 plus standard of care, for the treatment of lower extremity chronic, neuropathic diabetic foot ulcers

Registry ID
EUCTR2006-000692-15
Source registry
EUCTR
Status
Completed
Phase
PHASE2
Sponsor
Intercytex
Start date
2006-04-27
Completion date
2008-03-20
Last update
2026-08-16

Conditions

Summary

The primary safety objective is to determine the safety of ICXP007 plus standard of care in the treatment of chronic diabetic foot ulcers. The primary efficacy objective is to determine the efficacy of ICXP007 plus standard of care in achieving complete ulcer closure at 12 weeks in chronic, neuropathic diabetic foot ulcers of greater than four weeks duration.

Locations

View on source registry